Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

Vaccine

Volumn 30, Issue 36, 2012, Pages 5407-5416

  Gordon, David L ^a   Sajkov, Dimitar ^a   Woodman, Richard J ^b   Honda Okubo, Yoshikazu ^d   Cox, Manon M J ^c   Heinzel, Susanne ^d   Petrovsky, Nikolai ^a,d  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Protein Sciences Corp   (United States)

^d VAXINE PTY LTD   (Australia)

Author keywords

Adjuvant; Advax ; Antigen; Influenza; Pandemic; Recombinant; Vaccine

Indexed keywords

ADVAX; ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT HEMAGGLUTININ; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; OBSERVER VARIATION; PANDEMIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INULIN; MALE; MIDDLE AGED; PANDEMICS; POLYSACCHARIDES, BACTERIAL; VACCINES, DNA; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84864008199     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.009     Document Type: Article

References (50)

1. Chowell G., Bertozzi S.M., Colchero M.A., Lopez-Gatell H., Alpuche-Aranda C., Hernandez M., et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009, 361(August (7)):674-679.
2. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361(November (20)):1935-1944.
3. Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302(November (17)):1872-1879.
4. Webb S.A., Pettila V., Seppelt I., Bellomo R., Bailey M., Cooper D.J., et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361(November (20)):1925-1934.
5. Kotsimbos T., Waterer G., Jenkins C., Kelly P.M., Cheng A., Hancox R.J., et al. Influenza A/H1N1_09: Australia and New Zealand's winter of discontent. Am J Respir Crit Care Med 2010, 181(February (4)):300-306.
6. Wright P.F. Vaccine preparedness - are we ready for the next influenza pandemic?. N Engl J Med 2008, 358(June (24)):2540-2543.
7. Farnsworth A., Cyr T.D., Li C., Wang J., Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2011, 29(February (8)):1529-1533.
8. Garcia-Garcia L., Valdespino-Gomez J.L., Lazcano-Ponce E., Jimenez-Corona A., Higuera-Iglesias A., Cruz-Hervert P., et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 2009, 339:b3928.
9. Kucukosmanoglu E., Yazi D., Yesil O., Akkoc T., Gezer M., Bakirci N., et al. Prevalence of egg sensitization in Turkish infants based on skin prick test. Allergol Immunopathol (Madr) 2008, 36(May-June (3)):141-144.
10. Vierk K.A., Koehler K.M., Fein S.B., Street D.A. Prevalence of self-reported food allergy in American adults and use of food labels. J Allergy Clin Immunol 2007, 119(June (6)):1504-1510.
11. Vesikari T., Block S.L., Guerra F., Lattanzi M., Holmes S., Izu A., et al. Immunogenicity, safety, and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents 3 to 17 years of age. Pediatr Infect Dis J 2012, (February).
12. Ehrlich H.J., Singer J., Berezuk G., Fritsch S., Aichinger G., Hart M.K., et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012, 54(April (7)):946-954.
13. Kida H., Webster R.G., Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983, 76(2):91-99.
14. Yoden S., Kida H., Kuwabara M., Yanagawa R., Webster R.G. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res 1986, 4(May (3)):251-261.
15. The Public Health Emergency Medical Countermeasures Enterprise Review. 2010. Available from: http://www.phe.gov/preparedness/mcm/enterprisereview.
16. ® purified recombinant influenza hemagglutinin protein sciences corporation. FDA briefing document vaccines and related biological products advisory committee meeting 2009, 1-50.
17. Treanor J.J., El Sahly H., King J., Graham I., Izikson R., Kohberger R., et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29(October (44)):7733-7739.
18. Crawford J., Wilkinson B., Vosnesensky A., Smith G., Garcia M., Stone H., et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 1999, 17(May (18)):2265-2274.
19. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(February (13-14)):1732-1737.
20. Cooper P.D., Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-d-[2→1] poly(fructo-furanosyl) alpha-d-glucose polymers. Glycobiology 2011, 21(May (5)):595-606.
21. Lobigs M., Pavy M., Hall R.A., Lobigs P., Cooper P., Komiya T., et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91(June (Pt 6)):1407-1417.
22. Cristillo A.D., Ferrari M.G., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92(January (Pt 1)):128-140.
23. Layton R.C., Petrovsky N., Gigliotti A.P., Pollock Z., Knight J., Donart N., et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011, (July).
24. Wang K., Holtz K.M., Anderson K., Chubet R., Mahmoud W., Cox M.M. Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24(March (12)):2176-2185.
25. Webster RG, Cox N, Stöhr K. WHO manual on animal influenza diagnosis and surveillance (WHO/CDS/CSR/NCS/2002.5); 2002. Rev. 1, p. 37-9.
26. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(December (25)):2405-2413.
27. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(December (25)):2414-2423.
28. Sun F., Zhang Y., Tian D., Zheng M., Liu L., Zhang R., et al. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population - a practical observation. Vaccine 2011, 29(September (38)):6527-6531.
29. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(January (9708)):41-48.
30. Talaat K.R., Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Rockman S., et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010, 202(November (9)):1327-1337.
31. Geeraedts F., Bungener L., Pool J., ter Veer W., Wilschut J., Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Res Viruses 2008, 2(March (2)):41-51.
32. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008, 4(8):e1000138.
33. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 2007, 179(October (7)):4711-4720.
34. Jilg W., Schmidt M., Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989, 160(November (5)):766-769.
35. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136(April (7)):2348-2357.
36. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25(May (20)):4056-4063.
37. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
38. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(November (20)):1945-1952.
39. Webster R.G., Askonas B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 1980, 10(May (5)):396-401.
40. Fu T.M., Friedman A., Ulmer J.B., Liu M.A., Donnelly J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997, 71(April (4)):2715-2721.
41. Epstein S.L., Lo C.Y., Misplon J.A., Bennink J.R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998, 160(January (1)):322-327.
42. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18(February (2)):274-280.
43. Petrovsky N., Ross T.M. Challenges in improving influenza vaccine protection in the elderly. Expert Rev Vaccines 2011, 10(January (1)):7-11.
44. Roman F., Clement F., Dewe W., Walravens K., Maes C., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011, 18(May (5)):835-843.
45. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7(3):e33536.
46. Tan S., Gordon D.L., Honda-Okubo Y., Petrovsky N., Phillips P., Huddleston S., et al. Serological responses following influenza A H1N1 2009 infection in adults. J Infect 2011, 62(May (5)):388-393.
47. Johansson B.E., Brett I.C. Changing perspective on immunization against influenza. Vaccine 2007, 25(April (16)):3062-3065.
48. Precioso A.R., Miraglia J.L., Campos L.M., Goulart A.C., Timenetsky Mdo C., Cardoso M.R., et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine 2011, 29(November (48)):8974-8981.
49. Martelletti P., Granata M., Giacovazzo M. Serum interleukin-1 beta is increased in cluster headache. Cephalalgia 1993, 13(October (5)):343-345. (discussion 07-8).
50. Rainero I., Pinessi L., Salani G., Valfre W., Rivoiro C., Savi L., et al. A polymorphism in the interleukin-1alpha gene influences the clinical features of migraine. Headache 2002, 42(May (5)):337-340.